Synthesis of a celastrol derivative as a cancer stem cell inhibitor through regulation of the STAT3 pathway for treatment of ovarian cancer.

Accumulating evidence suggests that the root of drug chemoresistance in ovarian cancer is tightly associated with subpopulations of cancer stem cells (CSCs), whose activation is largely associated with signal transducer and activator of transcription 3 (STAT3) signaling. Recently, celastrol has shown a significant anti-cancer effect on ovarian cancer, but its clinical translation is very challenging due to its oral bioavailability and high organ toxicity. In this study, a celastrol derivative () was synthesized to augment the overall efficacy, and its underlying mechanisms were also explored. Different ovarian cancer cells, SKOV3 and A2780, were used to evaluate and compare the anticancer effects. displayed potent activities against all the tested ovarian cancer cells, with the lowest IC value of 0.14-0.25 μM. Further studies showed that effectively suppressed the colony formation and sphere formation ability, decreased the percentage of CD44CD24 and ALDH cells, and induced ROS production. Furthermore, western blot analysis indicated that significantly inhibited both Tyr705 and Ser727 phosphorylation and reduced the protein expression of STAT3. In addition, could dramatically induce apoptosis and cell cycle arrest, and inhibit migration and invasion. Importantly, showed a potent antitumor efficacy with no or limited systemic toxicity in mice xenograft models. The anticancer effect of is stronger than celastrol. attenuates cancer cell stemness, inhibits the STAT3 pathway, and exerts anti-ovarian cancer effects in cell and mouse models. Our data support that is a potent drug candidate for ovarian cancer.